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1. Introduction  
Individualizing drug therapy by the use of pharmacogenomics offers the opportunity to 
improve drug efficacy, reduce adverse side effects, and provide cost-effective 
pharmaceutical care. 6-mercaptopurine (6-MP), 6-thioguanine (6-TG) and azathioprine 
(AZA) are widely prescribed cytotoxic and immunosuppressive drugs used in the therapy 
of acute leukaemia, inflammatory bowel diseases, allograft rejections and others. 
The efficacy and toxicity of thiopurine drugs has been established to correlate with the 
extent of their deactivation by S-methylation. The discovery that the activity of thiopurine S-
methyltransferase (TPMT) in human tissues depends on the presence of germline single 
nucleotide polymorphisms (SNPs) led to one of the best examples of the successful clinical 
application of pharmacogenetic studies (Milek et al., 2006; R. Weinshilboum, 2001; R. M. 
Weinshilboum&Sladek, 1980). TPMT catalyzes the direct S-methylation of 6-MP to produce 
the inactive metabolite 6-methylmercaptopurine (6-MMP) leading to the lower toxic 
potential of the drug. Of more than 20 known polymorphisms in the TPMT gene, the most 
common variant alleles include TPMT*2, *3A and *3C. In Caucasian populations, 
individuals with homozygous variant and heterozygous genotypes have, respectively, low 
and intermediate TPMT activity, while individuals carrying the wild-type gene sequence 
exhibit a very wide range of high activity values. Patients with decreased TPMT activity are, 
when treated with standard doses of thiopurine medications, at greater risk of developing 
thiopurine induced toxicities, such as myelosupression, leucopenia and stomatitis (R. 
Weinshilboum, 2001).  
Homozygous patients with low or absent TPMT activity require a reduction to 10% of the 
standard dose, while heterozygous individuals should be administered 30-70%, depending 
on the initial treatment response (Relling et al., 2011). Predictive genotyping for the purpose 
of optimizing thiopurine treatment represents one of the best clinical applications of 
pharmacogenetic testing.  
In addition to being affected by genotype, TPMT activity is also regulated by a complex 
metabolic network. We and others have reported on the stabilization of TPMT by its co-
factor S-adenosylmethionine (SAM), which represents a candidate biomarker affecting 
TPMT activity and might to some extent explain the discordance between TPMT genotype 
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and phenotype (Milek et al., 2009; Scheuermann et al., 2004; Tai et al., 1997). In addition, it 
has been shown that polymorphisms in gene for MTHFR, the enzyme involved in SAM 
biosynthesis, correlate with the onset of hematotoxic events during the therapy of acute 
lymphoblastic leukaemia (ALL) (Karas-Kuzelicki et al., 2009).  
As the metabolism of SAM is closely related to the methionine cycle and the folate pathway, 
other endogenous metabolites, such as folates and methionine, as well as enzymes 
participating in their biosynthesis, might also indirectly influence TPMT activity.  
Both the identification and understanding of the factors influencing TPMT activity are 
crucial for improving the efficacy and safety of thiopurine therapy. 
2. Thiopurine drugs 
An ingenious idea, the purpose of which was to stop the growth of rapidly growing cells 
such as bacteria and tumours with modified nucleic acid bases was developed 
concomitantly with the discovery of DNA structure. A synthetic thiol-analogue of 
endogenous nucleic bases, thioguanine (6-TG), followed by 6-mercaptopurine (6-MP), and 
azathioprine (AZA), proved toxic to bacteria and tumours in mice. The initial experiments, 
conducted in 1948, were followed by clinical trials in 1953 and also present the basis for 
contemporary thiopurine therapy.  Gertrude Elion and George Hitchings were rewarded for 
this work with the Nobel Prize in Physiology or Medicine in 1988 (Marx, 1988). 
2.1 Mode of action 
The thiopurines, namely 6-marcaptopurine, azathioprine, and 6-thioguanine are inactive 
prodrugs which require intestinal absorption, cellular uptake and intracellular metabolism 
for their cytotoxic activity. The three main metabolic pathways for thiopurines are  
oxidation by xanthine oxidase (XO), phosphoribosylation by hypoxanthine-guanine 
phosphoribosyltransferase (HGPRT), and S-methylation by TPMT (R. Weinshilboum, 2001). 
Oxidation is a purely inactivating pathway, which is relevant only in non-hematopoietic 
cells, due to the restricted expression of XO in blood cells. Despite the fact that XO activity 
significantly varies among individuals, a molecular basis has not been completely 
delineated yet.   
The conversion of 6-MP by hypoxanthine phosphoribosyltransferase (HGPRT) yields 
thioinosine monophosphate (TIMP), which is further metabolized via inosine 5’-
monophosphate dehydrogenase (IMPD), guanosine monophosphate synthetase (GMPS), 
reductase and kinases to active thioguanine nucleotides (TGNs). Alternatively, TIMP can be 
methylated by thiopurine methyltransferase (TPMT) to 6-methylmercaptopurine 
ribonucleosides (6-MMPR), namely methylthioinosine monophosphate (MeTIMP), -
diphosphate (MeTIDP) and –triphosphate (MeTITP) (Fig.1). 
Incorporation of TGNs into DNA and RNA results in S phase arrest and programmed cell 
death, triggered via the mismatch repair pathway. On the other hand, MeTIMP is a potent 
inhibitor of de novo purine synthesis (DNPS), causing depletion of purine nucleotides, which 
results in cell growth arrest and cytotoxicity. DNPS inhibition is thought to be responsible 
for several adverse effects of thiopurines. Nevertheless, the incorporation of TGNs is 
considered to be the main mode of action of 6-MP (Relling et al., 1999). 
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Phosphorylation of TIMP by kinases yields 6-thioinosine triphosphate (TITP), which can be 
dephosphorylated back to TIMP by inosine triphosphatase (ITPA) (Derijks&Wong, 2010). 
 
 
Fig. 1. Metabolism of thiopurines. Azathioprine is converted to 6-mercaptopurine (6-MP) 
by a non-enzymatic process. Both 6-MP and 6-thioguanine (6-TG) are converted by the 
hypoxanthine–guanine phosphoribosyltransferase (HGPRT) into their respective nucleoside 
monophosphates (TIMP and TGMP). Thiopurine S-methyltransferase (TPMT) inactivates 6-
MP and 6-TG by S-methylation to form 6-methylmercaptopurine (6-MMP) and 6-
methylthioguanine (6-TGN), respectively. Xanthine oxidase (XO) inactivates 6-MP by 
converting it to 6-thiouric acid. TIMP and TGMP are also TPMT substrates, yielding 
methylated TIMP (meTIMP) and methylated TGMP (meTGMP). TIMP may also be 
phosphorylated to TIDP and TITP and dephosphorylated to TIMP by ITPA. TIMP that 
escapes catabolism is further metabolized by inosine monophosphate dehydrogenase 
(IMPD) and guanine monophosphate synthetase (GMPS) to TGMP. Sequential action of 
deoxynucleoside kinases and reductase generates the TGTP and dTGTP that are the 
substrates for incorporation of 6-TG into RNA and DNA, respectively. 
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The third metabolic pathway, catalyzed by TPMT, is S-methylation of thiopurine to 6-
methylmercaptopurine (6-MMP). This pathway is often referred to as being an inactivating 
pathway, since 6-MMP has no cytotoxic activity (Dervieux et al., 2001) (Fig. 1). 
2.2 Efficacy and safety of 6-MP in the treatment of ALL 
Acute lymphoblastic leukaemia is the most common malignancy in children. Treatment is 
stratified on the basis of various combinations of clinical and lymphoblastic characteristics 
in standard, intermediate and intensive therapy groups.  Different therapy protocols  have 
been and continue to be applied, such as USA Pediatric Oncology Group (POG) protocols 
and German Berlin-Frankfurt-Muenster (BFM) protocols (BFM-83, -86, -90, -95 and IC 2002). 
Treatment is generally composed of induction, consolidation and maintenance phases along 
with central nervous system prophylaxis (Moricke et al., 2008).  
The induction phase generally lasts 4-6 weeks and involves combinations of drugs including 
vincristine, prednisone, cyclophosphamide, doxorubicin, and L-asparaginase. This phase is 
followed by the consolidation phase with multiagent therapy including cytarabine and 
methotrexate. Maintenance therapy has been included in all protocols. It lasts from 1 to 3 
years and consists of 6-MP taken daily per os (50 mg/m2) and low weekly doses of oral 
methotrexate (MTX) (20 mg/m2) (Karas Kuzelicki et al., 2009). 
Due to the narrow therapeutic index, a certain level of side effect manifestations is expected 
in most patients treated with 6-MP.  We have investigated the occurrences of side effects in 
Slovenian pediatric ALL patients, identified through the national oncology patient registry. 
These patients had been treated with standard protocols at the University Children`s 
Hospital, University Medical Centre, Ljubljana, Slovenia in the period 1970-2004. The study 
group consisted of 313 ALL patients.  6-MP and other thiopurines were administered in all 
phases of ALL treatment. In order to investigate the occurrences of toxic effects and to 
exclude the influence of other drugs used in ALL treatment, we focused on the maintenance 
phase of the therapy, because it consisted exclusively of 6-MP and low dose MTX. The doses 
of 6-MP were calculated on the basis of a patient`s body surface (50 mg/m2) and adjusted 
during the treatment according to desired WBC counts, these being 2000 – 3000 WBC/μL.  
Therapy data, such as 6-MP dose reduction and the incidence of toxic effects including 
hematotoxicity, stomatitis, infections, and secondary tumours were obtained from patients’ 
charts for the maintenance phase of treatment protocols consisting exclusively of 6-MP and 
low dose MTX. 6-MP dose reduction greater than 10 % for a period longer than 3 months 
was considered significant. The toxic effect was defined as an event causing one of  
the following:  discontinuation of the therapy for longer than one week, a reduction of over 
10 % of 6-MP dose of a duration longer than 3 months, or the hospitalization of the patient. 
Hematotoxicity corresponded to grade 3 and 4 leukopenia, stomatitis to grade 2 and 3, 
infections to grade 3 and 4 and secondary tumours to grade 4 adverse events of National 
Cancer Institute Common Toxicity Criteria (version 2.0) (Karas Kuzelicki et al., 2009). 
The incidences of undesirable toxic effects are presented in Table 1. Despite the relatively 
high safety and efficacy of 6-MP,  a dose reduction was determined in 20 % of patients, 
hematotoxicity in 14 %, stomatitis in 5 %, infections in 21 %, and the incidence of secondary 
tumours in 4 % of patients. Our observations are also in concordance with other published 
data (Sanderson et al., 2004). 
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                          Side effects 
% Patients 
6-MP DR † HET ‡ Stomatitis ‡ Infections‡ 
Secondary 
TU 
Patients with the condition,  
n (%) 
63 
(20.2) 
44 
(14.1) 
14 
(4.5) 
67 
(21.4) 
13 
(4.1) 
Patients without the condition,  
n (%) 
249 
(79.8) 
269 
(85.9) 
299 
(95.5) 
246 
(78.6) 
300 
(95.9) 
6-MP DR, 6-MP dose reduction; HET, hematotoxicity; TU, tumours; n indicates number of subjects;  
† More than 10 % 6-MP dose reduction for a period of more than 3 months. 
‡ A 6-MP related toxic effect that caused the discontinuation of the therapy for more than one week, 
more than 10 % 6-MP dose reduction for a period of more than 3 months or hospitalization of the 
patient. 
Table 1. Analysis of 6-MP related toxic effects in Slovenian ALL patients  
2.3 Thiopurines in the immunosuppressive therapy  
Azathioprine (AZA) and 6-MP are the most widely used immunosuppressive agents in 
inflammatory bowel disease (IBD), examples of which being ulcerative colitis and Crohn’s 
disease. AZA is also indicated as an adjunct for the prevention of rejection in renal 
homotransplantations and for the management of active rheumatoid arthritis. Either alone 
or, more usually, in combination with corticosteroids and/or other drugs and procedures, 
AZA has been used in a proportion of patients suffering systemic lupus erythematosus, 
dermatomyositis and polymyositis, autoimmune chronic active hepatitis, pemphigus 
vulgaris, polyarteritis nodosa, autoimmune haemolytic anaemia and chronic refractory 
idiopathic thrombocytopenic purpura (IMURAN® (azathioprine). Product Information). On 
the other hand, 6-MP has been mostly used in either IBD or acute lymphoblastic leukaemia. 
Azathioprine was developed to prolong the half-life of 6-MP; therefore, a 1-methyl-4-nitro-5-
imidazole moiety was added to protect the reactive sulphur group from oxidation and 
hydrolysis. AZA was proven to have better immunomodulatory effects than 6-MP in 
preventing organ rejection in kidney transplants (Murray et al., 1963). It is postulated that 
this is associated with an effect of the methyl-nitro-imidazolyl substitute by a currently 
unknown mechanism. Although both drugs have been extensively used, they have proven 
ineffective in one-third of patients, while up to one-fifth of patients discontinue thiopurine 
therapy due to adverse reactions. The observed interindividual differences in therapeutic 
response and toxicity can, at least partly, be explained by genetic polymorphisms of the 
genes encoding crucial enzymes in thiopurine metabolism (Derijks&Wong, 2010). 
The reported frequencies of dose-dependent and dose-independent adverse effects of AZA 
and 6-MP are in the ranges of 1.4–5.0 % and 1.0–6.5 %, respectively. Myelotoxicity is 
considered a dose-dependent adverse effect that can be caused by elevated concentrations of 
the pharmacologically active 6-TGNs. On the other hand, dose-independent reactions are 
considered to be immune-mediated, and include rashes, arthralgia, hepatitis, myalgia, flu-
like symptoms, gastrointestinal complaints, fever and pancreatitis (de Boer et al., 2007)  
3. Individualization of thiopurine therapy 
Pharmacogenetic testing has been implemented in clinical practice for selected drugs only. 
The implementation of pharmacogenetics in the clinical setting was hampered by the 
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recognition that the metabolism of a given drug does not depend solely on a single drug-
metabolizing enzyme, but rather on a complex enzymatic network of competing metabolic 
pathways. It has become apparent that the identification of relevant pharmacogenetic 
markers is much more complicated than initially believed. 
Upon entering the cell, thiopurines are also subject to a complex metabolic network; their 
metabolic activation thus depends on genetic predisposition as well as nutritional and other 
environmental factors.  
3.1 Thiopurine S-methyltransferase (TPMT)  
Although TPMT pharmacogenetics is addressed in detail in a separate chapter of this book, 
we need to summarize the most relevant facts, since they are the basis for further 
elaborations. 
TPMT plays a pivotal role in thiopurine drug responses, such that decreased TPMT activity 
correlates with higher cytotoxic thioguanine nucleotide (TGN) levels which may result in 
life-threatening toxicity.  The distribution of TPMT activity in Caucasian populations is 
trimodal: approximately 89 % of population has normal to high, 11 % intermediate and 0.3 
% low or undetectable TPMT activity. Although numerous alleles have been identified, the 
most prevalent and clinically significant are TPMT*3A (460G>A and 719A>G), TPMT*3B 
(460G>A) and TPMT*3C (719A>G). TPMT genotyping prior to the initiation of thiopurine 
therapy represents a quick and reliable pharmacogenetic test. In accordance with advice 
provided by the FDA in 2004, the recommendation to perform the test before starting 
therapy with thiopurines has been included in the Summary of Product Characteristics 
(SmPC) of Purinethol® (6-MP) and Imuran® to highlight the usefulness of TPMT testing in 
predicting risk for thiopurine toxicity.  
TPMT deficient patients tend to be better responders to 6-MP therapy than wild-type 
patients- due to higher TGN accumulation in cancer cells- but are at greater risk of 
developing toxic effects such as hematotoxicity, infections, stomatitis and secondary 
tumours, as a consequence of their accumulation in normal cells. Conversely, ultra-high 
enzyme activity can lead to superior 6-MP tolerability but also to an increased risk of relapse 
and hepatic toxicity, which has been related to methylated metabolites of thiopurines 
(Evans, 2004).  
The clinical relevance of 6-MP dose reduction during maintenance therapy is well defined 
only in patients homozygous for variant TPMT alleles (TPMT*2, *3A, *3C) who exhibit low 
TPMT activity. Dosing adjustments based on TPMT status is recommended in thiopurine 
therapy. In the treatment of malignancies, conventional high doses of thiopurines are 
recommended for homozygous wild-type TPMT patients, while 30-70 % lower-than-normal 
starting doses should be used in heterozygous deficient patients, and at least 10-fold 
reduced doses in homozygous deficient patients (Relling et al., 2011). 
Due to an incomplete genotype-to-phenotype correlation in heterozygous individuals with 
variable intermediate activity, the predictive value of TPMT genotyping for the optimization 
of thiopurine therapy is limited. Therefore, the identification of novel pharmacogenetic 
and/or biochemical markers is necessary for high prediction. One such factor is S-
adenosylmethionine (SAM), which stabilizes the TPMT protein structure by binding to its 
active site (Scheuermann et al., 2004). Thus, SAM may also modulate TPMT activity in the 
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intercellular setting, possibly by post-translational stabilization. Consequently, the 
endogenous availability of SAM may influence TPMT activity, the formation of 6-MP 
metabolites, and the toxicity of thiopurine drugs. In addition, endogenous metabolites (e.g. 
folates, methionine, ATP) and enzymes participating in the biosynthesis of SAM, (e.g. 
MTHFR, TYMS), could also influence TPMT activity indirectly.  
3.2 The role of SAM in cellular metabolism and disease 
S-adenosyl-L-methionine (SAM) is one of the most abundant co-factors in eukaryotic cells 
and has been initially described as “active methionine” (Cantoni, 1951). It participates in 
many cellular processes and exerts many biological effects. As a pleiotropic molecule, it is 
the principal methyl donor in processes such as nucleic acid, protein and phospholipid 
methylation, acting as a co-substrate for many SAM-dependent methyltransferases (P. K. 
Chiang et al., 1996). In addition, it is an important regulator of replication, transcription and 
translation, acting on post-transcriptional and post-translational levels and by epigenetic 
mechanisms (Finkelstein, 2007). SAM is also involved in polyamine synthesis as well as 
inhibition of DNA demethylation (Detich et al., 2003), and plays an important role in cell 
growth, cell cycle progression and apoptosis (Loenen, 2006; Nitta et al., 2002).  
Cellular methylation is closely connected to the methionine cycle, methionine recycling 
pathway, folate metabolism, and polyamine synthesis, as well as transsulfuration and 
glutathione synthesis (Fig. 2) (Hitchler&Domann, 2007). Active metabolic conversions of the 
folate pathway and methionine (Met) cycle are ubiquitous, while transsulfuration takes 
place only in the liver, kidney, pancreas, intestinal tract and brain (Finkelstein, 2007). SAM 
and SAH act as efficient regulatory molecules in these processes, such that their molar ratio 
(i.e. methylation potential) determines the activity of many methyltransferases and related 
enzymes. 
SAM is synthesized from Met, the availability of which largely depends on folate pools and 
dietary intake. Tissue SAM levels thus depend on the expression of methionine 
adenosyltransferase (MAT), which catalyzes the conversion from Met, and 5,10-
methylenetetrahydrofolate reductase (MTHFR) that provides the substrate for the 
remethylation of homocysteine into Met. Mechanisms of SAM-induced metabolic regulation 
include the modulation of both tissue expression and kinetic properties of metabolizing 
enzymes as well as the concentrations of their substrates and products. Vice versa, the 
modified expression or enzyme activity of some methyltransferases has been shown to 
impact intracellular SAM and SAH levels, which are most notably determined by the 
expression of glycine N-methyltransferase (GNMT) (Luka et al., 2009). GNMT degrades 
excess SAM to SAH and decreases cell methylation capacity. Importantly, GNMT has been 
described as a key regulator of SAM level and methylation capacity in normal livers, while 
its expression is diminished in tumour tissue and cultured cells such as HepG2 (Martinez-
Chantar et al., 2008). 
Moreover, the modified activity of enzymes (e.g. methionine adenosyltransferase,  
S-adenosylhomocystein hydrolase) that catalyse the afore mentioned metabolic conversions 
significantly influences the dynamics and concentrations of metabolites; most prominently 
those of SAM and SAH, which have pleiotropic biological effects. In addition, aberrations  
in methylation and redox homeostasis have been implicated in several pathologies,  
such as liver carcinogenesis, hepatocellular carcinoma, chronic steatohepatitis and 
hyperhomocysteinemia-associated cardiovascular diseases (Martinez-Chantar et al., 2002a).  
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Fig. 2. SAM metabolism, the methionine cycle and related pathways. SAM is consumed in 
transmethylation reactions catalyzed by SAM-dependent methyltransferases (MT-ases). 
SAM has many diverse biological effects. Its metabolism is closely connected to 
homocysteine (Hcy) remethylation and methionine (Met) cycle, the folate pathway, 
transsulfuration, Met recycling pathway and polyamine synthesis. 5,10-Me-THF, 5,10-
methylenetetrahydrofolate; 5-Me-THF, 5-methyltetrahydrofolate; THF, tetrahydrofolate; 
MS, methionine synthase; MTHFR, 5,10-methylenetetrahydrofolate reductase; CBS, 
cystathionine-ǃ-synthase; Cys, cysteine; GSH, glutathione; SAHH, S-adenosylhomocysteine 
hydrolase; MAT, methionine adenosyltransferase; MTA, 5'-methylthioadenosine; MTAP, 5'-
methylthioadenosine phosphorylase;  Cys, cysteine; SAM, S-adenosylmethionine; SAMDC, 
SAM decarboxylase; TPMT, thiopurine S-methyltransferase, GNMT, glycine N-
methyltransferase. 
Unbalanced metabolic conversions in the methionine cycle are most frequently a 
consequence of a low dietary intake of folic acid, high alcohol consumption, poisoning, or 
genetic abnormalities. Most commonly, this is observed as hyperhomocysteinemia (i.e. 
elevated plasma homocysteine, Hcy), as well as SAM depletion, and consequently 
methionine metabolism related pathogenesis. Consequences of inactivated SAM, Met 
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synthesis and methionine adenosyltransferase activity have been well documented in 
patients with liver cyrosis and different forms of hyperhomocysteinemia (Martinez-Chantar 
et al., 2002b).  
3.3 The role of SAM in thiopurine metabolism 
SAM plays an important role in the intracellular conversions of thiopurines. The metabolism 
of 6-mercaptopurine and azathioprine results, apart from the synthesis of cytotoxic TGNs, 
cytosolic, in the production of methylated thiopurine metabolites (methylthioinosine 5’-
monofosphate, MeTIMP). These molecules act as antimetabolites by inhibiting 
phosphoribosyl pyrophosphate amidotransferase, the rate limiting enzyme in de novo purine 
synthesis (DNPS) pathways, which therefore leads to ineffective ATP production. Non-
depleted cellular ATP pools are required for SAM biosynthesis from Met catalyzed by 
methionine adenosyltransferase (MAT).  
The relevance of SAM in thiopurine metabolism has been demonstrated by several in vitro 
studies. Decreased SAM recycling via the methionine cycle was observed upon the addition 
of 6-MP or 6-methylmercaptopurine riboside (6-MMPR) to MOLT cells. Due to DNPS 
inhibition caused by the metabolite MeTIMP (Vogt et al., 1993), endogenous adenine 
nucleotide pools were depleted, limiting the ATP-dependent synthesis of SAM from 
methionine (Stet et al., 1994). The depletion of SAM also resulted in DNA hypomethylation 
(De Abreu et al., 1995). The inhibitory effect of 6-MMPR on the growth of MOLT 
lymphoblasts was reversed by supplementing adenine nucleotide pools with exogenous 
adenosine, adenine and inosine (Stet et al., 1995). Finally, exogenous SAM also prevents 6-
MP induced programmed cell death via the reduction of intracellular TGN and MeTIMP 
levels in MOLT cells (Milek et al., 2009). 
3.4 Effect of SAM-TPMT interaction on thiopurine drug action 
Since TPMT is a SAM-dependent methyltransferase, components of methionine 
metabolism are closely connected to thiopurine drug action. As in other reactions 
catalyzed by SAM-dependent methyltransferases, SAM provides the methyl group in the 
S-methylation of thiopurines, which is catalyzed by TPMT. As a side product in this 
process, SAM is converted to S-adenosylhomocysteine (Sahasranaman et al., 2008), a 
potent methyltransferase inhibitor. Apart from its role as a TPMT cofactor, SAM has been 
shown to exert additional effects on TPMT, in all probability as an efficient post-
translational regulator of its activity. 
Non-synonymous amino-acid substitutions resulting from common genetic polymorphisms 
destabilize TPMT protein structure and increase its susceptibility to proteasomal and 
autophagy-mediated degradation. The tridimensional structure of the yeast TPMT 
orthologue revealed that sinefungin, a SAM analogue, stabilizes the protein backbone 
towards a rigid native conformation, very possibly decreasing its susceptibility to 
proteolytic degradation (Scheuermann et al., 2004; Tai et al., 1999) (Fig. 3).  
A similar effect was observed for catechol-O-methyltransferase (COMT), a SAM-dependent 
methyltransferase, and for cystathionine ǃ–sythase (CBS), the rate limiting enzyme in the 
transsulfuration pathway (Prudova et al., 2006). In HepG2 cells SAM was found to modulate 
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its own production by destabilizing MAT2A mRNA, thus regulating the activity of MAT, 
the enzyme catalyzing SAM biosynthesis from Met (Martinez-Chantar et al., 2003). 
 
 
Fig. 3. Role of SAM in TPMT stability and degradation. Decreased tissue TPMT activity is a 
consequence of the rapid degradation of TPMT variant allozymes via the ubiquitin-
proteasome pathway. The binding of SAM to the TPMT protein structure restores 
intramolecular contacts and shifts the equilibrium towards a highly folded conformation 
that is less susceptible to intracellular proteolysis. SAM, S-adenosyl-L-methionine; TPMT, 
thiopurine S-methyltransferase; Ub, ubiquitin. 
Molecular and functional studies of TPMT SNPs have shown that non-synonymous amino-
acid substitutions in variant TPMT allozymes cause the disruption of intra-molecular van 
der Waals contacts (Scheuermann et al., 2003). Consequently, such variant proteins are 
readily degradable via proteasome- and autophagy-mediated proteolysis (Li et al., 2008; Tai 
et al., 1999). The addition of high concentrations of SAM, the principal cellular methyl donor 
and a co-substrate in the S-methylation reaction catalyzed by TPMT, resulted in increased 
TPMT activity in yeast extracts containing recombinant wild-type and TPMT*3C allozymes. 
The binding of SAM has also been shown to stabilize the 3D structure of the enzyme and 
shifts the dynamic balance towards the native structure, which prevents the proteolytic 
degradation of the enzyme. Most recently, exogenous SAM was shown to prevent 6-MP 
induced programmed cell death via the reduction of intracellular TGN and MeTIMP levels 
in MOLT cells, possibly by the post-translational stabilisaton of TPMT (Milek et al., 2009). A 
possible mechanism is indicated in Fig. 4. 
The most important evidence of SAM metabolism on TPMT stabilization was presented by 
two in vivo studies, where the presence of low-activity polymorphisms in 
methylenetetrahydrofolate reductase (MTHFR), the enzyme which catalyzes the formation 
of 5-methyltetrahydrofolate (5-Me-THF), a rate-determining step in the re-methylation of 
methionine from homocysteine (Fig. 2), has been found to correlate with decreased TPMT 
activity in patients with ALL (Arenas et al., 2005). It was postulated that low MTHFR 
activity results in limited SAM synthesis and, consequently, lower TPMT stability, observed 
as a modulation of the TPMT phenotype (Karas-Kuzelicki et al., 2009). 
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Fig. 4. SAM decreases thiopurine toxicity by stabilizing TPMT protein levels. In TPMT-
catalyzed reactions, SAM acts as a methyl donor, but can also stabilize the TPMT 3D 
structure (indicated by plus, encircled). This results in more extensive deactivation of the 
drug, i.e. the production of 6-methylmercaptopurine (6-MMP) as opposed to cytotoxic 
thioguanine nucleotides (TGN) and methylthioinosine monophosphate. Therefore, SAM 
indirectly decreases the extent of 6-methylmercaptopurine (6-MP) cytotoxicity in MOLT 
cells. TIMP, thioinosine monophosphate; SAM, S-adenosyl-L-methionine; TPMT, thiopurine 
S-methyltransferase. 
3.5 Synergistic effects of low activity TPMT and MTHFR on 6-MP-induced toxicity 
6-MP-induced toxic effects in TPMT heterozygous patients are augmented by a variant 
methylenetetrahydrofolate reductase (MTHFR) genotype. This is the case as SAM levels 
depend on the availability of folates, which themselves depend on the activity of MTHFR, 
the most important folate pathway regulating enzyme. 
MTHFR is an enzyme involved in the metabolism of folic acid, through the conversion of 
5,10- methylenetetrahydrofolate (5, 10-Me-THF) to 5-methyltetrahydrofolate (5-Me-THF). 
MTHFR is the rate-determining enzyme of the folate cycle, which plays a major role in 
methionine and SAM synthesis, and consequently affecting TPMT activity. This is 
demonstrated in homozygous and heterozygous MTHFR knockout mice (Chen et al., 2001), 
where decreased MTHFR activity leads to decreased SAM, increased homocysteine and 
SAH levels, and DNA hypomethylation.  In  humans, the low activity of MTHFR is coded 
by two alleles, 677 C>T and 1298 A>C. Homozygosity for 677 C>T and compound 
heterozygosity for 677 C>T and 1298 A>C is associated with increased blood homocysteine 
levels, while no apparent discrepancies in biochemical profile are detected in 1298 CC 
homozygotes (Botto&Yang, 2000; van der Put et al., 1998). These findings reflect enzymatic 
deficiency due to the presence of polymorphism.  MTHFR activity in homozygotes carrying 
two 677 C>T alleles is 40-50 % of the wild-type enzyme, while in 1298 A>C homozygotes the 
activity is somewhat higher but still below the normal range. The frequency of 677 T allele is 
lower in Africans (6-14 %) than in other races (25-43 %), and the highest frequencies have 
been documented for US Hispanics and Italians. Frequencies of the 1298 C allele are very 
similar, while the frequencies of compound heterozygosity for both variants range from 15 
to 20 % in Caucasian populations (Botto&Yang, 2000).  
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Individuals with the MTHFR 677 TT genotype have significantly lower serum folate levels 
(Nishio et al., 2008) and different ratio of methylated to formylated tetrahydrofolates (THF). 
While only the methylated forms of THF are present in wild-type individuals, up to 59 % of 
total RBC folates in 677 TT subjects were formyl-THF, as a consequence of lower MTHFR 
activity and decreased 5,10-Me-THF consumption for the formation of 5-Me-THF 
(Bagley&Selhub, 1998). Besides genetic predisposition, folate intake is crucial, as sufficient 
intake may diminish the effect of low-activity alleles. Similarly, the MTHFR 677 TT 
genotype in transformed human lymphoblasts is most significantly associated with the 
decreased SAM levels arising from decreased folate-dependent homocysteine re-
methylation under conditions of extracellular folate restriction (E. P. Chiang et al., 2007). 
These data suggest that the effect of genotype-dependent MTHFR status on methionine 
regeneration and SAM synthesis is also closely related to intracellular folate concentrations. 
A correlation between MTHFR and TPMT activity was demonstrated in individuals with 
intermediate TPMT activity carrying low activity 677 TT MTHFR and wild-type TPMT 
genotypes (Arenas et al., 2005). The influence of MTHFR activity on TPMT activity is also 
demonstrated in our recent study addressing the thiopurine toxicity in paediatric ALL 
patients. The synergistic effect of TPMT and MTHFR variant alleles was observed in 
patients carrying polymorphisms in both genes, and reflected in severe toxicity. 82 % of 
these patients experienced hematotoxicity, compared to 4 % of patients with wild-type 
MTHFR and TPMT genotypes. Similarly, patients carrying polymorphisms in both TPMT 
and MTHFR genes (59 %) were more likely to have experienced 6-MP dose reductions, as 
well as stomatitis and infections (Karas-Kuzelicki et al., 2008).  
3.6 Other potential pharmacogenetic markers in thiopurine therapy 
Individual responses to thiopurine therapy depend beside genetic predisposition, on 
nutritional and other environmental factors.  The genes and their variants identified so far 
do not suffice to fully justify the variability in drug response. Implementation of novel 
genetic and metabolomic findings is therefore crucial for the improved prediction of drug 
efficacy and safety. 
Xanthine oxidase (XO) is involved in the first-pass metabolism of 6-MP, and is 
predominantly expressed in the intestinal mucosa and liver. XO metabolizes 84 % of 6-MP 
into inactive 6-thiouric acid, resulting in a substantial reduction in 6-MP bioavailability. XO 
is an alternative name for Xanthine dehydrogenase (XDH), also termed Xanthine 
oxidoreductase, (XOR). XDH is a molybdenum-containing hydroxylase, readily converted to 
xanthine oxidase by reversible sulfhydryl oxidation or by irreversible proteolytic 
modification (http://omim.org/entry/607633). Numerous polymorphisms have been 
detected either in promoter or coding region of XDH/XO gene. The functional relevance of 
detected polymorphisms was determined in in vitro assays; in the allelic variants tested, a 
deficiency in enzyme activity was detected in two, low activity in six and high enzymatic 
activity in two (Kudo et al., 2008). In recent studies, a correlation of two polymorphisms in 
XO (1936 A>G and 2107 A>G) with the thiopurine therapy outcomes has been addressed; 
however, due to the small number of patients with myelotoxicity, it was not possible to 
draw any conclusions (Wong et al., 2007). 
Another potential polymorphic enzyme correlating with 6-MP toxicity is inosine triphosphate 
(ITP) pyrophosphatase (ITPA), which catalyses the pyrophosphohydrolysis of ITP into inosine 
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monophosphate, thereby preventing the accumulation of ITP in normal cells. Decreased ITPA 
activity leads to the accumulation of the inosine nucleotide, ITP in the cells. Recent studies 
have shown that the presence of P32T functional polymorphism in ITPA correlates with 
unwanted thiopurine toxicity in ALL patients. However, studies performed on patients with 
inflammatory bowel disease or on liver transplant recipients showed no association. 
Nevertheless, ITPA is emerging as an interesting candidate biomarker, even more so due to 
relatively high allele frequencies in some populations (Marsh&Van Booven, 2009). 
Thymidylate synthase (TYMS) is an enzyme that catalyzes the conversion of dUMP to 
dTMP by utilizing 5,10-Me-THF and, as such, constitutes a competing pathway for MTHFR-
catalyzed 5-Me-THF synthesis. Due to its considerable effect on 5-Me-THF levels and, 
consequently, on methionine and SAM synthesis, TYMS might, potentially, influence TPMT 
activity. There is a common tandem repeat polymorphism in the promoter region of TYMS, 
with the number of tandem repeats affecting TYMS activity levels, mediated through the 
effects of the repeats on translation efficiency (Kawakami et al., (1999, 2001)). The double 
repeat (2R) results in lower gene expression than the triple repeat (3R) (Horie et al., 1995). 
The 3R/3R genotype and high TYMS activity could lead to low 5-Me-THF, methionine and 
SAM levels and, consequently, low TPMT activity, resulting in higher TGN concentrations 
and a better therapy response (Karas-Kuzelicki&Mlinaric-Rascan, 2009).  
In addition, several other polymorphic genes encoding crucial enzymes of thiopurine 
metabolism, such as glutathione S-tranferases, hypoxanthine phosphoribosyltransferase, 
inosine monophosphate dehydrogenase and multidrug resistance proteins, have been 
described and represent novel pharmacogenetic markers influencing thiopurine therapy 
(Derijks&Wong, 2010). 
4. Future directions and clinical application  
The effective stabilization of TPMT by SAM, which prevents thiopurine toxicity, has several 
clinical implications. An in vitro study showed that in patients receiving 6-MP, a decrease in 
TPMT activity may be expected after 6-MP administration, due to DNPS inhibition and 
decreased synthesis of the stabilising factor SAM. In patients with wild-type or heterozygous 
mutant TPMT genotypes, who exhibit high and intermediate TPMT activities respectively, a 
decrease in the enzyme activity may result in an overproduction of TGNs, increasing the risk 
of undesirable toxicity. On the other hand, high levels of endogenous SAM, as well as potential 
compensatory responses to SAM depletion, may contribute to the detoxification of the drug, 
and, consequently, lead to the wild-type patients being non-responders, by decreasing the 
production of cytotoxic TGNs. The availability of folate pools may also significantly influence 
6-MP related cytotoxic effects, since the metabolic fluxes of homocysteine remethylation and 
downstream SAM synthesis are folate dependent. The mechanism described in the present 
study could, therefore, play an important role in patients receiving folates in dietary 
supplements during thiopurine treatment, modulating the amount of SAM, and, consequently, 
TPMT activity. Further in vivo studies of the correlation of TPMT with the activity of enzymes 
involved in SAM metabolism, (e.g. methionine adenosyltransferase, S-adenosylmethionine 
decarboxylase, 5,10-methylenetetrahydrofolate reductase), could reveal additional factors 
influencing treatment with 6-MP. Moreover, the presence of activity-modulating genetic 
polymorphisms in these enzymes could explain the poor TPMT genotype-to-phenotype 
correlations observed in some individuals. 
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Detailed and relevant understanding of TPMT regulation by SAM in the context of Met 
metabolism in several cell lines, primary cells, animal models and human samples is a 
valuable resource for the improved prediction of clinical outcomes. Further studies will 
have direct consequences in the clinic, by improving the genotype-to-phenotype correlation 
in heterozygous and wild-type individuals with unexpectedly low TPMT activity. 
Furthermore, novel factors influencing TPMT activity and thiopurine drug response will 
enable a much more realistic implementation of existing genetic and biochemical test(s) in 
clinical practice. In fact, effective antidotes that rapidly decrease thiopurine toxicity by 
acting as positive regulators of TPMT levels and thiopurine deactivation would be 
substantially favourable in the clinical setting. 
4.1 Methods for measuring SAM 
Given the critical role of SAM in many metabolic pathways and its importance in the 
diagnosis of various pathological manifestations, as well as its potential implication in 
individualization of thiopurine therapy, the development of an accurate, sensitive and 
reproducible method for its quantification is very important. 
Various methods for the analysis of SAM in different tissues have been developed in the last 
two decades. Most of the developed methods are HPLC-based and use UV detection 
(Bottiglieri, 1990; Molloy et al., 1990; Wise et al., 1997) with either ion-pairing or cation 
exchange chromatography. Some of them use fluorescent detection after conversion of the 
analytes to fluorescent analogs (Capdevila&Wagner, 1998; Loehrer et al., 1996), others 
electrochemical detection (Melnyk et al., 2000).  
HPLC methods combined with ultraviolet detection are suitable for measuring the 
concentrations of SAM in tissues, including red blood cells, where SAM can be found in the 
micromolar range, whereas methods with fluorescent detection show greater sensitivity and 
can also be used for the detection of SAM in plasma in nanomolar concentrations. In order 
to enable even better quantification of SAM presented in plasma or cerebrospinal fluid in 
low nanomolar concentration, some more sensitive LC–MS (Stabler&Allen, 2004) and LC–
MS/MS methods (Gellekink et al., 2005; Struys et al., 2000) have also been developed. 
A capillary electrophoresis method has been developed for the determination of SAM and 
SAH in rat liver and kidney as well as in mouse liver, but it can also be used to determine 
SAM in whole blood (Uthus, 2003).  
The stereospecific colorimetric assay for (S,S)-SAM quantification is based on TPMT-
catalyzed thiol methylation. All reagents are commercially available and inexpensive, and 
the necessary enzymes are robust and readily obtainable in large quantities from 
recombinant sources. The assay can be carried out on UV–visible spectrometers available in 
most laboratories and can be adapted for batch assay, for example, in a microplate format. 
The method is linear from 5 μM to at least 60 μM (S,S)-SAM. The higher limits of the assay 
are restricted by the linear range of individual spectrophotometers at 410 nm, whereas the 
lower limits are determined by the sensitivity and precision of the spectrophotometer. 
Although the method was developed to determine SAM concentration in tablets, it could 
also be applied to measure SAM concentration in physiological fluids (Cannon et al., 2002).  
The commercially available assay for SAM determination is a Mediomics Bridge-It® 
fluorescence assay based on a combination of fluorescence measurement techniques and an 
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assay platform design that utilizes DNA-binding proteins as biosensors for their respective 
ligands. The affinity of the DNA-binding transcriptional repressor MetJ, labelled with 
fluorophore, for its DNA-binding site is greatly increased in the presence of its ligand, SAM. 
This method exhibits a high signal to background ratio, a broad linear dynamic range (0.5 
µM – 20 µM), and a detection sensitivity of 0.5 µM; therefore, it is useful for the purpose of 
quantifying SAM in various samples including biological fluids, cell culture and 
fermentation medium, and extracts of tissues and cells  (www.mediomics.com). 
5. S-adenosylmethionine (SAM) in therapy 
SAM in the form of its stable p-toluensulphonate or butanedisulfonate salt has been used for 
more than 20 years in the treatment of depression, liver disorders, and musculoskeletal and 
joint disorders such as osteoarthritis and fibromyalgia. It has been available as a prescription 
drug marketed under different brand names (Gumbal, Samyr, Adomet, Heptral and 
Admethionine) in Italy, Spain, Germany, the Czech Republic, Russia, Argentina and Mexico, 
whereas in the United States and Canada SAM has been available under the Dietary 
Supplement and Health Education Act as a nutritional supplement under the marketing 
name SAM-e. 
Depression 
Although the mechanism of antidepressant action of SAM is not entirely clear, it is thought 
that its ability to function as a methyl donor increases brain levels of serotonin, dopamine, 
and norepinephrine. It has been previously reported that serum and cerebrospinal fluid 
levels of SAM are low in depressed patients (Bottiglieri 1990; Lakhan 2008) and that 
increases in serum SAM levels correlate with improved treatment response (Bell 1994). 
Besides the stimulatory effect of SAM on central monoaminergic neurotransmitters, there 
may exist alternative mechanisms in which increased or restored membrane phospholipid 
methylation plays a role in the antidepressant effect. SAM may increase the fluidity of cell 
membranes by stimulating phospholipid methylation, which has previously been linked to 
an increase in ß receptor and muscarinic (M1) receptor density (Bottiglieri, 2002).  
SAM has been studied for use in various depressive disorders for many decades, with the 
first clinical trials dating back to as early as 1973 (Fazio et al., 1973). The majority of studies 
performed since then have reported that SAM is effective for treating depression, the 
conclusion also drawn later by a meta-analysis (Bressa, 1994) and some other systematic 
reviews (Williams 2005; Papakostas 2003; Mischoulon 2002). However, due to several 
quality issues and methodological flaws of the individual studies included in these reviews, 
the findings should be interpreted with caution. Most studies are quite dated (1970s or 
1980s), have short treatment duration and are of small sample size (n < 50). Furthermore, the 
most appropriate daily dosage for SAM is also not well established. Due to its low oral 
bioavailability, many of the earlier SAM studies utilized parenteral formulations 
(intramuscular or intravenous), which may also limit the clinical relevance of those studies 
(Carpenter, 2011).  
Osteoarthritis 
SAM has also been studied extensively in the context of the treatment of osteoarthritis. 
Experimental studies indicate that SAM increases the chondrocyte proteoglycan synthesis and 
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proliferation rate. SAM induces the synthesis of polyamines that might stabilize the 
polyanionic macromolecules of proteoglycans and protect them from attack by proteolytic and 
glycotic enzymes. Furthermore, in vitro studies show that SAM can antagonize the tumour 
necrosis factor ǂ–induced decreases in synovial cell proliferation and fibronectin mRNA 
expression. These findings indicate that SAM restores basal conditions in cultured synovial 
cells after cytokine-induced cell damage (Bottiglieri, 2002). Many trials have demonstrated that 
SAM reduces the pain associated with osteoarthritis and is well tolerated in this patient 
population. However, a systematic review (Rutjes et al., 2009) found that available studies 
were mainly small and of questionable quality, and that, therefore, the routine use of SAM for 
osteoarthritis of the knee or hip could not be recommended until such time as further 
evaluation through larger randomised controlled studies has taken place.  
Liver Disease 
SAM has been used to treat various types of acute and chronic liver diseases. Although the 
focus of clinical trials in this area has been diffuse, a number of clinical trials have focused 
on the effect of SAM on cholestasis arising from a variety of causes, including pregnancy 
(Almasio et al., 1990; Frezza et al., 1990a; Frezza et al., 1990b). SAM may exert beneficial 
effects on the liver through a variety of mechanisms. Glutathione, the major anti-oxidant in 
the liver, plays a key role in detoxification and the limiting of oxidative damage. Studies 
have shown that abnormal SAM synthesis is associated with chronic liver disease, 
regardless of its etiology. At customary therapeutic doses, SAM has been shown to increase 
hepatic glutathione concentrations in patients with chronic liver disease (Chawla et al., 
1990). Although some studies have demonstrated clinical improvement in patients with 
intrahepatic cholestasis, hepatic steatosis and alcoholic liver cirrhosis, a systematic review of 
9 randomised placebo-controlled studies could not find evidence to support or refute the 
claim that SAM has a beneficial effect in patients with alcoholic liver disease 
(Rambaldi&Gluud, 2006).  
Neurological Disorders 
Several studies indicate that a CNS methyl group deficiency may play a role in the etiology of 
Alzheimer disease (AD). Hyperhomocysteinemia, often related to folate or vitamin B 12 
deficiency, is a common finding in the elderly and is associated with cognitive impairment and 
cognitive decline. The association between hyperhomocysteinemia and AD is well established; 
however, the underlying pathophysiology remains unexplained. Studies in cell culture 
experiments and mouse models have suggested that 2 metabolites of homocysteine, SAM and 
S- adenosylhomocysteine (Sahasranaman et al., 2008), may be important in Alzheimer 
pathogenesis, e.g. by influencing the expression of presenilin 1 and ǃ - secretase, leading to an 
increase in Aǃ production (Linnebank et al., 2010). It is important to note that the use of either 
SAM or alternative methyl group donors (such as betaine or folate and vitamin B-12) might 
improve measures of cognitive function. These treatments may be able to restore methyl group 
metabolism and normalize blood homocysteine concentrations (Bottiglieri, 2002).  
6. Conclusions 
Prediction of TPMT activity and thiopurine drug response based on TPMT genotyping tests 
represents one of the most relevant applications of pharmacogenetics. Prediction of TPMT 
activity and treatment response solely on the basis of presence of mutant TPMT alleles is 
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insufficient, due to the incomplete TPMT phenotype-to-genotype correlation. This problem 
is most pronounced in heterozygous patients (8-10 % in Caucasian populations), which 
exhibit a wide range of intermediate enzyme activity, and in those wild-type individuals 
which do not exhibit high activity. Hence, to improve the prediction of thiopurine therapy 
outcome, identification of new biomarkers is essential.  
One of such candidates is SAM, which, by binding into the active site of TPMT, stabilizes its 
structure. Several studies suggest that measurement of erythrocyte SAM level, in addition to 
TPMT genotyping, could serve as an additional predictor of TPMT activity in some 
thiopurine patient subgroups, and suggest that stabilization of TPMT by SAM has 
substantial clinical relevance. Some analytical methods for the determination of SAM in 
biological samples have already been described which are suitable for the implementation 
into clinical practice.  
In addition, SAM, which has been used for more than 20 years in the treatment of 
depression, liver disorders, and musculoskeletal and joint disorders, may be a promising 
agent to acutely regulate TPMT activity in order to rapidly decrease excess thiopurine 
toxicity in some patient subgroups. 
In addition to measuring SAM levels in red blood cells, analyses of genes directly or 
indirectly involved in the folate metabolism (such as MTHFR and TYMS) can add valuable 
additional information to conventional TPMT genotyping, thus enabling the development of 
complex diagnostic algorithms, and in turn improving the efficacy and safety of the 
thiopurine therapy. 
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